Eva Kubala Havrdova

Eva Kubala Havrdova is an expert in Neurology at General University Hospital in Prague (Czechia). As of October 2026, ScienceLeadR ranks Eva Kubala Havrdova in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases, and in the top 1% of experts in Czechia for Secondary Progressive Multiple Sclerosis. Eva Kubala Havrdova has authored 675 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 1 of them ongoing. SLR score: 1,894 (community average: 125). How the SLR is computed.

Neurology

Subspecialties: Immunology - Neurosurgery - Psychiatry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 10, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026

Source: PubMed

Charles University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 675

Citations

Citations: 44 744 1st author: 27 Last author: 60 Unique author: 4

Main journals

Neurology 185

Mult Scler 87

Mult Scler Relat Disord 46

J Neurol Neurosurg Psychiatry 31

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
How patients with neuromyelitis optica spectrum disease accumulate disability. PMID 42847346 — multiple sclerosis, absenteeism, central nervous system diseases, cohort studies, neuromyelitis optica, demyelinating diseases	Mult Scler	2026
Erratum to "Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years" [Multiple Sclerosis and Related Disorders, Volume 67, November 2022, 104187]. PMID 42705801 — sclerosis, multiple sclerosis, disease progression	Mult Scler Relat Disord	2026
Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years. PMID 42561748 — sclerosis, multiple sclerosis, safety, therapeutics, wounds and injuries, multiple sclerosis, relapsing-remitting	Mult Scler Relat Disord	2026
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study. PMID 42543909 — sclerosis, multiple sclerosis, neoplasms, drug therapy, diagnosis, therapeutics, chemotherapy	Mult Scler	2026
Causal effects of multiple sclerosis therapies in left-truncated registry data. PMID 42479470 — registries, sclerosis, multiple sclerosis, bias, demyelinating diseases, therapeutics	Mult Scler	2026

Clinical Studies 26

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 17

Phase 2 6

N/A 2

Phase 4 1

By status:

Completed 22

Terminated 2

Active not recruiting 1

Unknown 1

By type:

Interventional 25

Observational 1

By Monocentric/Multicentric:

monocentric 4

multicentric2to4 0

multicentric5to9 0

multicentricup10 22

Main Topics

Immune System Diseases 25

Nervous System Diseases 25

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Rollover Study to Evaluate the Long Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis 2023-505974-14-00 — sclerosis, multiple sclerosis, safety	Phase 3	Active not recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice